Fluidigm Technology Accelerates the Adoption and Impact of Single-Cell
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Nature Publishing Group has
selected single-cell sequencing as its Method of the Year for 2013
(www.nature.com/nmeth/index.html). The publication, in explaining its choice,
noted that "methods to sequence the DNA and RNA of single cells are poised to
transform many areas of biology and medicine." The publication continued:
"Single-cell genome and transcriptome sequencing methods are generating a fresh
wave of biological insights into development, cancer and neuroscience."
Fluidigm, an industry-leader in single-cell genomics, has pioneered products
capable of elucidating the benefits of understanding biology at the level of the
individual cell. Today, most sequencing is performed on tissue samples, a
genomic stew of cell populations in which biological differences between cells
at the molecular level are hidden by averaging the signal of all the cells into
one averaged value.
According to Nature, "Single-cell methods offer a way to dissect this
heterogeneity. Single-cell DNA sequencing can reveal mutations and structural
changes in the genomes of cancer cells, which tend to have high mutation rates.
This information can be used to describe the clonal structure and to trace the
evolution and spread of the disease. These approaches are also revealing a
surprising level of mosaicism in somatic tissues such as the brain, the
functional consequences of which will need to be elucidated in the coming
Until now, a substantial proportion of single-cell research has focused on
imaging -- relying upon microscopy to differentiate cell populations based upon
phenotypic characteristics; however, a growing body of scientific research has
demonstrated that cells with the same size, shape and immunophenotype exhibit
significant differences in expression and genomic variation at the molecular
level. Single-cell sequencing is enabling researchers to define new molecular
profiles for sub-populations. Researchers are also able to monitor these
molecular changes as cells are activated, observe cells develop, and track how
cells respond to environmental stimuli.
"This is an excellent choice by the editorial board of Nature Methods," said
Gajus Worthington, Fluidigm president and chief executive officer. "The
scientific contributions of our customers, enabled by single-cell genomics, have
been profound. There are now more than 100 peer-reviewed single-cell
publications based on Fluidigm technology. We are part of a growing community
that believes single-cell genomics will broadly and fundamentally revolutionize
Worthington continued, "The timing of this announcement by Nature Methods
represents a bit of serendipity as we just announced our new single-cell DNA
sequencing workflow for our C1 System days ago."
Fluidigm Single-Cell Technology
Fluidigm has developed a unique approach to single-cell genomics based on its
microfluidic technology. Its innovative technologies enable highly parallel RNA
and DNA analysis from samples containing only a few hundred cells. By
integrating and simplifying multiple steps in a universal sample prep workflow
for single-cell DNA sequencing (targeted, whole exome and whole genome
sequencing) researchers can rapidly and reliably isolate, process, and profile
individual cells for multiple genomics applications.
Last week, Fluidigm announced a universal sample prep workflow for single-cell
DNA sequencing that runs on its C1TM Single-Cell Auto Prep System. This workflow
streamlines targeted, whole exome and whole genome sequencing in heterogeneous
cell populations and enables researchers to discover and screen somatic
mutations, such as SNP, small indels, and translocations. Somatic mutations are
non-inherited, random mutations that are accumulated over time and may play an
important role in the origin and progression of complex diseases, such as aging,
cancer, immunity, and neurodegenerative disorders.
Earlier this year, Fluidigm released a protocol for single-cell mRNA sequencing
to support whole transcriptome analysis. This key application enables
researchers to measure the differential expression across the transcriptome
within cell sub-populations as well as to identify novel transcripts and
alternate splicing patterns. The protocol has been widely accepted by several
major institutions around the globe and resulted in two Nature Methods
publications in 2013.
In addition to sequencing, Fluidigm's technology allows single-cell gene
expression measurement that is revolutionizing the understanding of gene
regulation and settling many biological debates that have raged for years.
Single-Cell Genomics is a Growing Market
DeciBio, a market research firm, estimated in its first edition of its
Single-Cell Genomics: Market Size, Segmentation, Growth, Competition and Trends
Report (published August 2013), that they expect the current market for
single-cell genomics to grow to $540 million by 2018 (39% CAGR). In the report,
DeciBio states its "...analysis and interviews with experts suggests that
single-cell genomics is at a tipping point. DeciBio believes that similar to
qPCR in the 1990s, all the right drivers are in place (high scientific interest,
rapidly growing number of publications, and optimized instruments and reagents)
to really 'unlock' this market."
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements relating
to Fluidigm's new products, its plans, objectives, expectations and/or
strategies relating to such new products, the field of single-cell genomics
research and potential developments in the emerging market. Forward-looking
statements are subject to numerous risks and uncertainties that could cause
actual results to differ materially from currently anticipated results,
including challenges inherent in developing, manufacturing, and launching new
products and risks relating to research and development activities and the
growth of emerging markets. Information on these and additional risks affecting
Fluidigm's business and operating results are contained in its filings with the
Securities and Exchange Commission, including its most recently filed Quarterly
Report on Form 10-Q for the quarter ended September 30, 2013. These
forward-looking statements speak only as of the date hereof and Fluidigm
disclaims any obligation to update these statements.
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets microfluidic systems
to leading academic institutions, clinical laboratories, and pharmaceutical,
biotechnology, and agricultural biotechnology companies in growth markets, such
as single-cell genomics, applied genotyping, and sample preparation for targeted
resequencing. Fluidigm's proprietary microfluidic systems consist of instruments
and consumables, including 18 different commercial integrated fluidic circuits
for nucleic acid analysis, and three families of assay chemistries. These
systems are designed to significantly simplify experimental workflow, increase
throughput, and reduce costs, while providing the excellent data quality
demanded by customers. Fluidigm products are provided: For Research Use Only.
Not for use in diagnostic procedures.
For more information, please visit www.fluidigm.com.
Fluidigm, C1, and the Fluidigm logo are trademarks or registered trademarks of
Howard High, 650-266-6081 (office)
Fellow, Corporate Communication and Press Relations
Source: Fluidigm Corporation